Advertisement

China Medical Technologies Inc. said Wednesday that it received Chinese regulatory approval for its genetic test aimed at improving the targeted use of lung cancer drugs.

The company said the State Food and Drug Administration of China approved the PCR-based Epidermal Growth Factor Receptor Assay.

Shares of China Medical fell 30 cents to $11.51 in morning trading.

Advertisement
Advertisement